We can’t show the full text here under this license. Use the link below to read it at the source.
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
AI simplified
Abstract
In a cohort of 354 patients using semaglutide, 52.5% achieved an HbA1c of < 7.0% and 34.2% attained a weight loss of ≥ 5%.
- Greater reductions in HbA1c and weight were observed in the semaglutide subgroup compared to the broader OW GLP-1RA cohort.
- OW GLP-1RAs significantly outperformed DPP-4is in reducing HbA1c (-1.5% vs. -1.0%) and weight (-3.2 kg vs. -1.0 kg).
- The semaglutide cohort also demonstrated superior effectiveness in HbA1c reduction (-1.7% vs. -0.9%) and weight loss (-4.1 kg vs. -1.3 kg) compared to DPP-4is.
- Patients starting OW GLP-1RAs were at least twice as likely to meet HbA1c and weight loss goals as those starting DPP-4is.
- Results indicate that OW GLP-1RAs may be more effective for glycemic control and weight reduction in people with type 2 diabetes in real-world settings.
AI simplified
Key numbers
-1.5%
HbA Reduction (OW GLP-1RAs vs. DPP-4is)
OW GLP-1RAs reduced HbA by -1.5% vs. -1.0% for DPP-4is.
-3.2 kg
Weight Loss (OW GLP-1RAs vs. DPP-4is)
OW GLP-1RAs led to a weight loss of -3.2 kg vs. -1.0 kg for DPP-4is.
52.5%
Achievement of HbA < 7.0% ()
52.5% of the subgroup achieved HbA < 7.0%.